Li Kang Biomedical Co Ltd
Li Kang Biomedical Co., Ltd. manufactures and sells supplement, cosmeceutical, and hygienic drink products. It also engages in the management and consulting of tourism factory business; and offers telemarketing services. The company was formerly known as BAFO Technologies Corporation and changed its name to Li Kang Biomedical Co., Ltd. in September 2014. Li Kang Biomedical Co., Ltd. was founded i… Read more
Li Kang Biomedical Co Ltd (6242) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.007x
Based on the latest financial reports, Li Kang Biomedical Co Ltd (6242) has a cash flow conversion efficiency ratio of -0.007x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-5.95 Million) by net assets (NT$843.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Li Kang Biomedical Co Ltd - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how Li Kang Biomedical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Li Kang Biomedical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Li Kang Biomedical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DAIHAN Scientific Co. Ltd
KQ:131220
|
0.006x |
|
Compass Gold Corporation
PINK:COGDF
|
-0.005x |
|
Isaac Engineering Co. Ltd.
KQ:351330
|
0.029x |
|
Sumit Woods Limited
NSE:SUMIT
|
0.002x |
|
ATOME ENERGY PLC LS-002
F:J6J
|
N/A |
|
Ossiam Lux - Ossiam Shiller Barclays CAPE US Sector Value Trust
F:USCP
|
N/A |
|
IHQ Inc
KO:003560
|
0.072x |
|
Atenor S.A.
LSE:0NG6
|
-0.102x |
Annual Cash Flow Conversion Efficiency for Li Kang Biomedical Co Ltd (2002–2024)
The table below shows the annual cash flow conversion efficiency of Li Kang Biomedical Co Ltd from 2002 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$855.68 Million | NT$65.38 Million | 0.076x | -50.24% |
| 2023-12-31 | NT$630.03 Million | NT$96.74 Million | 0.154x | -44.32% |
| 2022-12-31 | NT$570.14 Million | NT$157.24 Million | 0.276x | +124.49% |
| 2021-12-31 | NT$492.00 Million | NT$60.45 Million | 0.123x | -23.53% |
| 2020-12-31 | NT$508.30 Million | NT$81.67 Million | 0.161x | -16.08% |
| 2019-12-31 | NT$483.44 Million | NT$92.56 Million | 0.191x | -15.29% |
| 2018-12-31 | NT$466.92 Million | NT$105.53 Million | 0.226x | -8.94% |
| 2017-12-31 | NT$445.68 Million | NT$110.61 Million | 0.248x | -23.67% |
| 2016-12-31 | NT$340.80 Million | NT$110.82 Million | 0.325x | +42.61% |
| 2015-12-31 | NT$280.29 Million | NT$63.91 Million | 0.228x | +24.49% |
| 2014-12-31 | NT$227.44 Million | NT$41.66 Million | 0.183x | -18.77% |
| 2009-12-31 | NT$128.49 Million | NT$28.97 Million | 0.225x | +1252.82% |
| 2003-12-31 | NT$338.06 Million | NT$5.63 Million | 0.017x | -87.37% |
| 2002-12-31 | NT$347.64 Million | NT$45.87 Million | 0.132x | -- |